Latest filing published 13 Dec 2024 for Lumos Pharma, INC.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Lori D. Lawley, listed as finance chief, appears in our data through filings on Lumos Pharma, Inc. shares, published by SEC (Form 4). We count 11 filings; the first trade dates from 1 August 2021 and the latest from 12 December 2024.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
The latest filing, published on 13 December 2024, reports a transaction in Lumos Pharma, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
11 of 11 declarations